mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival
Metrics: PDF 454 views | HTML 1244 views | ?
Ana-Barbara García-García1,2,*, M. Carmen Gómez-Mateo3,7,*, Rebeca Hilario2, Pilar Rentero-Garrido2, Alvaro Martínez-Domenech4, Veronica Gonzalez-Albert2, Andres Cervantes5, Pablo Marín-Garcia6, Felipe Javier Chaves1,2, Antonio Ferrández-Izquierdo3 and Luis Sabater4
1CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain
2Unidad de Genómica y Diagnóstico Genético. Fundación Investigación Clínico de Valencia, Instituto de Investigación Sanitaria Clínico de Valencia (INCLIVA), Valencia, Spain
3Department of Pathology, Faculty of Medicine and Odontology, University of Valencia and Clinical Hospital of Valencia, and Instituto de Investigación Sanitaria Clínico de Valencia (INCLIVA), Valencia, Spain
4Department of Surgery, University of Valencia, Hospital Clínico Universitario, Instituto de Investigación Sanitaria Clínico de Valencia (INCLIVA), Valencia, Spain
5Hematology and Medical Oncology Unit, Biomedical Research Institute INCLIVA and Department of Medicine, University of Valencia, Valencia, Spain
6Bioinformatics Unit. Fundación Investigación Clínico de Valencia, Instituto de Investigación Sanitaria Clínico de Valencia (INCLIVA), Valencia, Spain
7Current/Present address: Pathology Department, Hospital Universitario Donostia, San Sebastian, Spain
*These authors have contributed equally to this work
Felipe Javier Chaves, email: email@example.com
Keywords: pancreatic ductal adenocarcinoma; gene expression; patient survival; microdissected cells; regional lymph node metastases
Received: July 22, 2016 Accepted: July 17, 2017 Published: August 03, 2017
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most devastating malignancies in developed countries because of its very poor prognosis and high mortality rates. By the time PDAC is usually diagnosed only 20-25% of patients are candidates for surgery, and the rate of survival for this cancer is low even when a patient with PDAC does undergo surgery. Lymph node invasion is an extremely bad prognosis factor for this disease.
Methods: We analyzed the mRNA expression profile in 30 PDAC samples from patients with resectable local disease (stages I and II). Neoplastic cells were isolated by laser-microdissection in order to avoid sample ‘contamination’ by non-tumor cells. Due to important differences in the prognoses of PDAC patients with and without lymph node involvement (stage IIB and stages I-IIA, respectively), we also analyzed the association between the mRNA expression profiles from these groups of patients and their survival.
Results: We identified expression profiles associated with patient survival in the whole patient cohort and in each group (stage IIB samples or stage I-IIA samples). Our results indicate that survival-associated genes are different in the groups with and without affected lymph nodes. Survival curves indicate that these expression profiles can help physicians to improve the prognostic classification of patients based on these profiles.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.